Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Oncopeptides AB at Cowen Healthcare Conference (Virtual) Transcript

Mar 03, 2021 / 04:00PM GMT
Release Date Price: kr134.3 (-2.01%)
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Hello. My name is Boris Peaker. I'm one of the biotech analysts here at Cowen. It's my pleasure to introduce Marty Duvall from Oncopeptides. Marty is the Chief Executive Officer of the company, and we look forward to hearing their presentation. Marty?

Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Thanks, Boris. Great to be here, and thanks to everybody for joining us. Really excited here at Oncopeptides. As you may have heard on Friday evening, we received FDA approval for PEPAXTO, our new product for relapse and refractory multiple myeloma.

So I'll be making some forward-looking statements here during the course of my presentation, so please refer to our filings for fair balance.

So with the approval of PEPAXTO now by the FDA, we have transformed into a fully integrated biotech company. Really excited about our company from an end-to-end perspective, starting with the discovery an IND generation. As you may know, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot